Clinical Information Search
Search Results for "diabetes_articles"
- Online Learning Center (0)
- Policy Library (103)
- Performance Measures (0)
- Annals of Internal Medicine (1952)
- Annals of Internal Medicine: Clinical Cases (143)
- IM Matters (6)
- ACP Hospitalist (42)
- ACP Diabetes Monthly (58)
- ACP Gastroenterology Monthly (4)
Sorry, no results were found for "diabetes_articles" in Online Learning Center.
Sorry, no results were found for "diabetes_articles" in Performance Measures.
Displaying 191 - 200 of 1952 in Annals of Internal Medicine
These Annals of Internal Medicine results only contain recent articles.
- Visit annals.org to search all content back to 1927.
- View Annals of Internal Medicine CME by topic here.
In type 2 diabetes, weekly semaglutide reduced HbA1c and increased weight loss more than weekly exenatide ER
Source Citation Ahmann AJ, Capehorn M, Charpentier G, et al. Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial. Diabetes Care. 2018;41:258-66. 29246950
Intensive weight management in primary care improved weight loss and remission of type 2 diabetes
Source Citation Lean ME, Leslie WS, Barnes AC, et al. Primary care–led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet. 2017. [Epub ahead of print]. 29221645
Review: Newer second-line drugs for diabetes are not more cost-effective than sulfonylureas
Source Citation CADTH Therapeutic Reviews. New drugs for type 2 diabetes: second-line therapy–science report. Ottawa, ON: Canadian Agency for Drugs and Technologies in Health; Sep 2017.
In type 2 diabetes with CVD and kidney disease, empagliflozin reduced mortality and hospitalization
Source Citation Wanner C, Lachin JM, Inzucchi SE, et al; EMPA-REG OUTCOME Investigators. Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease. Circulation. 2018;137:119-29. 28904068
Review: In diabetes, intensive and standard glycemic control do not differ for end-stage kidney disease or death
Source Citation Ruospo M, Saglimbene VM, Palmer SC, et al. Glucose targets for preventing diabetic kidney disease and its progression. Cochrane Database Syst Rev. 2017;6:CD010137. 28594069
Self-monitoring of blood glucose did not improve HbA1c or QoL at 1 year in non–insulin-treated type 2 diabetes
Source Citation Young LA, Buse JB, Weaver MA, et al; Monitor Trial Group. Glucose self-monitoring in non-insulin-treated patients with type 2 diabetes in primary care settings: a randomized trial. JAMA Intern Med. 2017;177:920-9. 28600913
In type 1 diabetes, education with either insulin pumps or daily injections did not differ for HbA1c at 2 y
Source Citation REPOSE study group, Heller S, Amiel S, et al. Relative effectiveness of insulin pump treatment over multiple daily injections and structured education during flexible intensive insulin treatment for type 1 diabetes: cluster randomised trial (REPOSE). BMJ. 2017;356:j1285. 28360027
Review: Dapagliflozin increases, and empagliflozin reduces, adverse renal events in type 2 diabetes
Source Citation Tang H, Li D, Zhang J, et al. Sodium–glucose cotransporter 2 inhibitors and risk of adverse renal outcomes among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2017 Feb 27 [Epub ahead of print]. 28240446
Exenatide did not reduce major cardiovascular outcomes in type 2 diabetes
Source Citation Holman RR, Bethel MA, Mentz RJ, et al; EXSCEL Study Group. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377:1228-39. 28910237
Liraglutide reduced a composite renal outcome at a median 4 y in patients with type 2 diabetes and high CV risk
Source Citation Mann JFE, Ørsted DD, Brown-Frandsen K, et al; LEADER Steering Committee and Investigators. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med. 2017;377:839-48. 28854085